Connable Office Inc’s AbbVie ABBV Stock Holding History

Connable Office Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,611	Closed	-$1.59M	–	225
2025 Q1	$1.59M	Buy	+7,611	New	+$1.48M	0.17%	76
2022 Q3	–	Sell	-16,126	Closed	-$2.47M	–	204
2022 Q2	$2.47M	Buy	+16,126	New	+$2.46M	0.38%	46

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Connable Office Inc's ABBV Position: Q2 2025 in Review

Connable Office Inc sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 7,611 shares — an estimated $1.59M sold.

Connable Office Inc first reported a position in ABBV in Q2 2022 and held it in 2 quarters. The position peaked at $2.47M in Q2 2022. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Connable Office Inc reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
Connable Office Inc sold 7,611 AbbVie shares in Q2 2025, an estimated $1.59M.
Connable Office Inc first reported a position in AbbVie in Q2 2022 and held it in 2 quarters.
Connable Office Inc's AbbVie position peaked at $2.47M in Q2 2022.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Connable Office Inc's 13F filing for Q2 2025, filed 5 Aug 2025.